Platelets and heart failure

被引：104

作者：

Chung, Irene ^{[1
]}

Lip, Gregory Y. H. ^{[1
]}

机构：

[1] Univ Birmingham, City Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B18 7QH, W Midlands, England

来源：

EUROPEAN HEART JOURNAL | 2006年 / 27卷 / 22期

关键词：

platelet activation; heart failure; CD40L; P-selectin; antiplatelet therapy;

D O I：

10.1093/eurheartj/ehl305

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heart failure is associated with increased risk of venous thromboembolism, stroke, and sudden death. Platelet abnormalities have been well described in heart failure but the significance of platelets in contributing to the thromboembolic complications of heart failure remains uncertain. Furthermore, the role of antiplatelet agents in heart failure remains unclear. This review will focus on platelet activation and the role of platelet dysfunction in heart failure, with particular regard to pathophysiology and outcome. The effects of heart failure therapeutics on platelet function and antiplatelet therapy in heart failure will also be discussed.

引用

收藏

页码：2623 / 2631

页数：9

相关论文

共 72 条

[1] Role of catecholamines in platelet function: Pathophysiological and clinical significance [J].

Anfossi, G ;

Trovati, M .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1996, 26 (05) :353-370

[2]

[Anonymous], 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003333

[3] Elevated circulating levels of C-C chemokines in patients with congestive heart failure [J].

Aukrust, P ;

Ueland, T ;

Müller, F ;

Andreassen, AK ;

Nordoy, I ;

Aas, H ;

Kjekshus, J ;

Simonsen, S ;

Froland, SS ;

Gullestad, L .

CIRCULATION, 1998, 97 (12) :1136-1143

[4]

Badimon L, 1999, THROMB HAEMOSTASIS, V82, P1736

[5]

Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71

[6] THE EFFECT OF NIFEDIPINE AND CAPTOPRIL ON PLATELET ACTIVATION AND PROSTANOID PRODUCTION IN ESSENTIAL-HYPERTENSION [J].

BIRKEBAEK, NH ;

VEJBYCHRISTENSEN, H ;

JAKOBSEN, P ;

WINTHER, K .

JOURNAL OF HYPERTENSION, 1988, 6 :S378-S380

[7] Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure [J].

Chin, BSP ;

Blann, AD ;

Gibbs, CR ;

Chung, NAY ;

Conway, DG ;

Lip, GYH .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 (11) :941-948

[8] Clinical trials update and cumulative meta-analyses from the American College of cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure [J].

Cleland, JGE ;

Ghosh, J ;

Freemantle, N ;

Kaye, GC ;

Nasir, M ;

Clark, AL ;

Coletta, AP .

EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (04) :501-508

[9] The Warfarin/Aspirin Study in Heart failure (WASH): A randomized trial comparing antithrombotic strategies for patients with heart failure [J].

Cleland, JGF ;

Findlay, I ;

Jafri, S ;

Sutton, G ;

Falk, R ;

Bulpitt, C ;

Prentice, C ;

Ford, I ;

Trainer, A ;

Poole-Wilson, PA .

AMERICAN HEART JOURNAL, 2004, 148 (01) :157-164

[10] Efficacy of antithrombotic therapy in chronic heart failure: The HELAS study [J].

Cokkinos, DV ;

Haralabopoulos, GC ;

Kostis, JB ;

Toutouzas, PK .

EUROPEAN JOURNAL OF HEART FAILURE, 2006, 8 (04) :428-432

← 1 2 3 4 5 6 7 8 →